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DNA methylation plays a fundamental role in the regulation of the genome, but the optimal strategy for analysis of
genome-wide DNA methylation data remains to be determined. We developed a comprehensive analysis pipeline
for epigenome-wide association studies (EWAS) using the Illumina Infinium HumanMethylation450 BeadChip, based
on 2,687 individuals, with 36 samples measured in duplicate. We propose new approaches to quality control, data
normalisation and batch correction through control-probe adjustment and establish a null hypothesis for EWAS
using permutation testing. Our analysis pipeline outperforms existing approaches, enabling accurate identification
of methylation quantitative trait loci for hypothesis driven follow-up experiments.Background
DNA methylation is involved in the regulation of nu-
merous biological processes, including gene expression
[1], cell differentiation [2] and X-chromosome inactiva-
tion [3]. Altered DNA methylation has been linked to
complex human diseases including cancer [4], schizo-
phrenia [5], multiple sclerosis [6] and type 2 diabetes
[7-9]. Recent technological developments, in particular
the release of the Illumina Infinium HumanMethyla-
tion450 BeadChip (450 K methylation array), make it
possible to measure DNA methylation on a genome-
wide scale [10]. However, the 450 K methylation array
includes multiple different probe types, each using dif-
ferent chemistry. Furthermore the methylation assay in-
volves bisulphite conversion of DNA and other steps
that introduce assay variability and batch effects. Mul-
tiple methods have been proposed for analysis of the* Correspondence: b.lehne@imperial.ac.uk; j.chambers@imperial.ac.uk
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unless otherwise stated.complex data generated by the 450 K methylation array
[11-17]; however, there is currently no consensus on the
optimal analysis pipeline.
We propose a comprehensive approach to the analysis
of 450 K methylation array data. Our method was devel-
oped using data from over 2,600 samples from the London
Life Sciences Prospective Population (LOLIPOP) study,
including 36 samples measured in duplicate and identifies
differential methylation on a single-marker level. Our
pipeline, termed CPACOR (incorporating Control Probe
Adjustment and reduction of global CORrelation), per-
forms superiorly to published methods, and provides a
blueprint for the analysis of large-scale Epigenome-Wide
Association Studies (EWAS).Results and discussion
Initial quantification and quality control
We analysed two DNA methylation datasets: a population
study of type 2 diabetes comprising 2,687 samples; and a
technical replication dataset comprising 36 samples mea-
sured in duplicate (Materials and Methods). To maximise
the impact of technical factors in the replication dataset,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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separate batches.
We performed an initial top-level quality control fol-
lowing analysis recommendations given by Illumina. We
excluded 22 samples (sample call rate <98% or incorrect
gender). The distributions for methylation values differ
between autosomal and gender chromosome markers
(Additional file 1: Figure S1); we therefore analyse these
separately. Markers that are predicted to cross-hybridise
[18], with a SNP in the probe-sequence, or that measure
methylation at non-CpG sites were retained but flagged.
Evaluating the detection P value threshold
We initially used a detection P value of P <0.05 for
marker calling based on Illumina recommendations. We
noted though that calculated detection P values reported
by minfi [15] range from 1 to 2.2 × 10−16, with values
lower than 2.2 × 10−16 reported as zero (Additional file 1:
Figure S2). To investigate the impact of detection P value
threshold, we first evaluated call rates on the Y-
chromosome among females in the population study;
these are expected to be zero for all 416 markers. In
contrast, we found that >50% of Y-chromosome
markers had non-zero call rates in females (Figure 1),
suggesting that the default detection P value (P <0.05)
is not sufficient to prevent spurious results. When the
detection P value threshold is lowered to P <10−16 the
proportion of Y-chromosome markers with non-zero
call rate in females is reduced from 55% to 10%. The
majority of these remaining markers represent previ-
ously unidentified cross-hybridising probes (Additional
file 1: Table S1). A more stringent detection thresholdFigure 1 Marker call rates on the Y-chromosome. Distribution of call ra
and females (green bars). Y-chromosome markers in females are represente
cross-hybridise with multiple genomic regions. Values greater than 80 are r
than 50% of Y-chromosome markers show non-zero call rates (call rate >0.0
(B) For a detection threshold P <10−16 only 10% of Y-chromosome marker
in red) are not materially affected by the more stringent detection P valuedoes not impact materially on Y-chromosome calling
in males (Figure 1 and Additional file 1: Figure S3).
To extend these findings to autosomal markers, we
quantified the proportion of extreme values (outliers) at
each marker in the population study as a metric for
quality of marker calling (Methods). Adoption of a more
stringent detection P value threshold (P <10−16) reduces
the proportion of outlying values, especially at markers
with lower call rates, consistent with improved calling
(Additional file 1: Figure S4).
As a final test, we compared results for the 36 samples
that were measured in duplicate. We observe a higher
correlation (P = 2.91 × 10−11) between duplicate pairs
when a detection P value threshold of P <10−16 is ap-
plied compared to a threshold P <0.05 (Additional file 1:
Figure S5), providing further evidence for improved
quantification of methylation with a more stringent de-
tection P value threshold.
This approach provides a roadmap for researchers to
determine the detection P value threshold that is optimal
for their dataset. Based on our results, we chose P <10−16
as detection P value threshold, providing a high accuracy
at minimal loss of data. We recalculated sample call rates
and excluded one further sample from the population
study dataset with a call rate below 98% leaving 2,664
samples for further analysis.
Data normalisation
Data normalisation is frequently applied in the analysis
of microarray data to reduce technical biases across
measurements. To establish a consensus approach for
normalisation of the 450 K methylation array wetes for 416 Y-chromosome markers in males (red points and red line)
d in light green if their respective probes sequences are predicted to
epresented by numbers. (A) For a detection threshold P <0.05 more
5%) in females, even though females do not possess a Y chromosome.
s show non-zero call rates in females. Marker call rates in males (shown
threshold.
Figure 2 Correcting for statistical inflation due to technical
biases. Quantile-Quantile (QQ) plot for the comparison of 36 samples
measured in duplicate reveals high statistical inflation before (Genomic
Inflation Factor λraw = 12.74; brown points) and after quantile
normalisation (λQN = 2.11; green points) due to technical biases.
Batch-correction based on control probes removes technical biases
and statistical inflation (λCP = 1.01; green points).
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methods [11,14,18-21] using the relationship between
beta values for the 36 samples measured in duplicate
(Additional file 1: Figure S6). The highest correlations
between the paired measurements of methylation were
achieved after quantile normalisation of intensity values
for markers, subdivided by probe type, probe sub-type
and colour channel (Additional file 1: Figure S7 and S8,
Table S2). Functional normalisation (FN) [22], subset
within array normalisation (SWAN) [20] and quantile
normalisation of beta values performed significantly
worse, while within-array approaches showed little or no
improvement compared to non-normalised data.
While correlation between technical replicates as-
sesses Type-I statistical error, it may not assess over-
normalisation. To quantify the ability to detect true
signal after each normalisation method, we performed
spike-in simulations based on the population study.
Case–control status was randomly assigned to samples
and beta values of 100 randomly selected markers were
increased (‘spiked’) in the case samples. We then deter-
mined the proportion of the spiked markers that were
ranked in the top 100 methylation markers by univari-
ate regression analysis. Confirming our initial finding,
quantile normalisation of intensity values performs
best, followed by quantile normalisation of beta values
and subset quantile normalisation. Whereas most methods
lead to improved performance, some over-normalise
resulting in a reduction of true signal compared to no nor-
malisation (Additional file 1: Figure S9; Table S3).
On the basis of these results, which are in agreement
with previous findings [23,24], we performed quantile
normalisation of intensity values for all samples in this
study.
Removal of technical biases
To investigate whether there were remaining technical
biases after quantile normalisation, we used linear re-
gression to compare the paired measurements of beta
values from the 36 samples measured in duplicate. We
observed a high degree of statistical inflation (λ = 2.11,
Figure 2) indicating strong residual biases between the
duplicates, consistent with batch and other technical
effects.
Existing methods to further reduce technical biases re-
quire knowledge of relevant experimental factors such as
bisulfite conversion batch, array number, position on
array, date or time [25]. These data may not be available,
or where available may not accurately measure the tech-
nical bias (Additional file 1: Figure S10). To overcome
these limitations and improve upon existing approaches,
we developed Control Probe Adjustment as a new
method to correct for technical biases in the 450 K
methylation data. We first retrieved signal intensities forthe 450 K methylation array control probes, which assess
multiple aspects of the chemistry involved in quantifica-
tion of methylation, such as bisulfite-conversion effi-
ciency (Additional file 1: Table S4). To take into account
the high degree of correlation between these control
probes (Additional file 1: Figure S11), we performed a
principal component analysis (PCA) of control probe in-
tensities, and then included the principal components
(PCs) as linear predictors in the regression analysis of
the 36 samples measured in duplicate. The PCs correlated
closely with multiple technical parameters, including bi-
sulfite batch and plates (Additional file 1: Figure S12).
Adjustment for the first 30 PCs almost entirely removed
test statistic inflation consistent with effective correc-
tion for batch and technical effects (λ = 1.01; Figure 2,
Additional file 1: Figure S13).
To further evaluate this strategy, we applied Control
Probe Adjustment to the population study of 2,664 sam-
ples. This effectively removed the biases introduced by
known technical factors (Additional file 1: Figure S14).
Null hypothesis and global correlation patterns
To determine the P value distribution under the null hy-
pothesis we randomly re-assigned case–control status
among the 2,664 samples of the population study and
performed a logistic regression for each marker using
quantile normalised beta values and adjusting for control
probe PCs. We repeated this 1,000 times to give 1,000
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tion of the case–control status to remove true associ-
ation we observed substantial departure from the null
expectation. This includes both overall statistical defla-
tion for the majority of permutations, but also a small
number of permutations with a high degree of statistical
inflation (λmedian = 0.96; λ2.5%tile = 0.84; λ97.5%tile = 1.46,
Figure 3A).
Theoretically expected P values are based on the as-
sumption of independence for each test. In contrast we
observe a high degree of correlation (and anti-correlation)
between 1,000 randomly chosen markers (Additional file 1:
Figure S15). We hypothesised that this correlation be-
tween markers reduces the number of independent tests
and may explain the apparent deflation of P values. To
test this hypothesis, we randomly reassigned beta values
for each marker to re-establish independence between
markers. This effectively abolished test-statistics deflation
and revealed a narrow prediction interval around the
expected (λmedian = 1.00; λ2.5%tile = 1.00; λ97.5%tile = 1.01;
Additional file 1: Figure S16).
Factors driving global correlation patterns
Correlation between methylation markers may arise
from technical and biological confounders. We therefore
carried out a further PCA of the population study data-
set to identify the primary patterns of covariation
between the genome-wide measurements of autosomalFigure 3 Prediction interval under the null hypothesis of no associati
of the case–control status. The λ-value represents the median (2.5 percenti
normalisation and adjustment for control probe PCs. Under no association
statistical inflation for a small number of permutations. (B) Quantile norma
cells and PC1-5. Adjustments abolishes overall statistical deflation and resulmethylation in peripheral blood. We then used the PCs
to explore relationships of methylation to technical and
biological factors (Figure 4).
The first three PCs were strongly associated with mul-
tiple white blood cell sub-populations. To further ex-
plore this aspect we generated a complementary set of
white blood cell subpopulations, which were estimated
from the methylation data itself [26]. The estimated
white blood cell subsets accurately reproduce white
blood cell measurements (Pearson correlation coefficient
r = 0.82-0.56; Additional file 1: Figure S17), but provide
cell type proportions of four additional lymphocyte sub-
populations. We also found significant correlations of
PCs with age, but not with any other clinical variables.
Adjustment for biological factors in the population
samples reduced the correlation between markers and
test statistic inflation, with the greatest reduction result-
ing from adjustment for white blood cell subpopulations
(Additional file 1: Figure S18-S19). To make a final cor-
rection for global covariation that is still unaccounted by
the biological factors included in the regression we per-
formed a final PCA of the residuals after adjustment for
technical and biological factors. Adjustment for the first
five PCs (which explain 3.7% of the variation; Additional
file 1: Figure S20), further reduced the correlation between
markers (λmedian = 1.00; λ2.5%tile = 0.97; λ97.5%tile = 1.05;
Figure 3B). On the basis of these results we calculated a
95% prediction interval and propose an epigenome wideon. Quantile-quantile (QQ) prediction intervals for 1,000 permutations
le to 97.5 percentile) of all genomic inflation factors λ. (A) Quantile
we observe and overall statistical deflation, but also a high degree of
lisation, adjustment for control probe PCs, gender, age, white blood
ts in a substantially more narrow prediction interval.
Figure 4 Principal component analysis identifies global correlation patterns. We carried out a PCA of the methylation data (based on
residuals after quantile normalisation and Control Probe Adjustment) to identify the primary patterns of covariation and used the PCs to explore
relationships to biological factors such as measured (m) and estimated (e) white blood-cell subsets, gender, age and others. Colours represent
P values for correlation of different factors with PCs 1 to 10.
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approximately 470,000 independent tests.
Impact on local correlation
Previous studies have reported an increased degree of
correlation between neighbouring CpG sites (<1 kb dis-
tance) [27,28], which are likely to reflect biologically
functional units. We replicated these findings, and also
show that our adjustments for technical and biological
factors remove correlation between markers with a high
genomic distance (>1 kb) while retaining correlation be-
tween markers in direct genomic neighbourhood (<1 kb)
(Additional file 1: Figure S21, Table S5). These observa-
tions support the view that our approach to data analysis
preferentially removes the long-range correlations be-
tween markers that are more likely to be spurious.
Performance
We used simulated case–control datasets to assess the
performance of the CPACOR analysis pipeline (Figure 5,Additional file 1: Table S6). Based on the spike-in approach
described above, we show that the proportion of spiked
markers achieving high rank is improved successively by
each of the stages of our pipeline including quantile nor-
malisation, adjustment for control probes, and adjustment
for biological factors (Figure 6, Additional file 1: Table S7).
We conclude that these adjustments increase the power
to identify true association signals and reduce system-
atic biases between samples.
We used simulations to compare the performance of
our analysis pipeline with published methods [11-17].
This analysis focuses on single marker comparisons to
identify differentially methylated CpG sites, rather than
a multi-marker approach [29] to avoid regional biases
introduced by the non-random selection of CpG sites
targeted by the HumanMethylation450 BeadChip [10].
We found that most of the published methods could not
be completed using datasets of >2,000 samples, even on
a dedicated high-performance computing cluster with
2 TB of RAM (Additional file 1: Figure S22; Table S8).
Figure 5 Workflow of CPACOR (incorporating Control Probe Adjustment and reduction of global CORrelation) for Epigenome-wide
Association Studies using the Illumina HumanMethylation450 BeadChip. Signal intensities are filtered for multiple Quality Control criteria
followed by quantile normalisation and calculation of beta values. In addition intensities from Illumina control probes are used to derive principal
components (control-probe PCs). Based on beta values, proportions of white blood cell subpopulations are estimated and PCs are derived (from
intermediary residuals; see Methods for details). To detect differential methylation regression analysis is performed for each methylation marker
predicting disease status as a function of the (quantile normalised) beta value adjusted for technical and biological factors and PCs.
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performance through parallelisation. Although different
methylation studies may require different approaches to
analysis, results from spiked data of a smaller dataset
(250 cases, 250 controls) indicate that CPACOR performs
significantly better than published methods (Additional
file 1: Figure S22, Tables S9 and S10).
Adjustment using reference-free approaches
Reduction of statistical inflation is crucial for the analysis
of EWAS. Here we use direct adjustment for known bio-
logical confounders to achieve this. Several recently devel-
oped methods for epigenome-wide association attempt to
adjust for biological confounders without prior knowledge
or reference datasets [30,31]. These so-called ‘reference-
free’ approaches attempt to correct for biological con-
founders by identifying clusters of covariation in the dataand removing this covariation by adjustment. For ex-
ample, the EWASher method [30] attempts to reduce stat-
istical inflation by constructing a methylation similarity
matrix based on CpGs most strongly associated with the
endpoint. It includes this similarity matrix as the covari-
ance component in a Linear Mixed Model (LMM) regres-
sion. However, because this adjustment is based on
methylation values of the most strongly associated CpGs,
this approach may remove variation attributable to the
endpoint (Additional file 1: Figure S23).
RefReeEWAS, a different reference-free approach, ex-
cludes variation attributable to the endpoint before adjust-
ment [31]. However, we find that it performs substantially
less well than CPACOR (Additional file 1: Figure S24).
This may partly be explained by the very considerable
computational requirement which limit the number of
bootstraps for deriving P values.
Figure 6 Simulation analysis shows successive improvement of
each stage of the CPACOR pipeline. We increased (‘spiked’) beta
values of 100 randomly selected markers and determined the
proportion of the spiked markers that were ranked among the
top 100. The proportion of spiked markers achieving top 100
ranks is improved successively by each of the stages of the
CPACOR pipeline.
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form less well than the direct adjustment implemented
in our pipeline. However, for tissue samples where
relevant reference datasets are not available these ap-
proaches may provide a strategy to reduce statistical
inflation.
Marker subtypes and sex chromosomes
To investigate for potential biases arising from other
marker specific properties, we assessed the impact of
markers in three categories (Materials and methods): (1)
non-CpG markers; (2) cross-hybridising markers; and
(3) markers with a SNP in the probe-sequence (Add-
itional file 1: Table S11). We found very little evidence
to suggest these markers reduce overall data quality. In-
cluding them during quantile normalisation does not
materially affect correlation between technical duplicates
(mean r = 0.9979 in both cases). P value distributions
under no association show no evidence that non-CpG
markers or markers with SNPs in the probe sequence
are more likely to generate spurious results, but we ob-
serve a slight increase in correlation for cross-hybridising
markers (Additional file 1: Figure S25). We therefore rec-
ommend retaining, but flagging these markers.
Adjustment for technical and biological factors also
reduces correlation between markers on the sex chro-
mosomes, although to a lesser extent than autosomal
markers, resulting in broader prediction intervals(Additional file 1: Figure S26). This suggests a higher
probability of both Type-1 and Type-2 errors during
analysis of sex-chromosome data, compared to auto-
somal results.
Conclusions
The emergence of the Illumina 450 k methylation array
now enables investigation of the relationships between
DNA methylation and phenotype in population studies.
We provide a blueprint for an EWAS analysis pipeline
based on data from the Illumina 450 Methylation array.
We show that the default detection P value is insuffi-
ciently stringent to prevent spurious results, identify the
optimal approach to data normalisation, describe a new,
highly effective method for dealing with technical bias,
and demonstrate the importance of accounting for bio-
logical confounders. On the basis of these results we
demonstrate an epigenome-wide significance threshold
of P <10−7, that is consistent with Bonferroni correction.
We show that our approach significantly outperforms
existing methods for identification of true association.
Furthermore our approach is scalable and, unlike many
existing methods, capable of handling large-scale data-
sets involving several thousand samples. Our compre-
hensive set of instructions for the analysis of Illumina
450 k methylation will advance the ability of EWAS to
accurately identify methylation quantitative trait loci for
hypothesis driven follow-up experiments.
Materials and methods
In the first section we describe in detail the consecutive
steps of our EWAS analysis pipeline. The corresponding
scripts are provided in Additional file 2 (usage requires
knowledge of R-programming and scripts may have to
be adapted to the user’s hardware and software require-
ments). The subsequent sections provide details on data
generation and additional analyses performed to compare
and evaluate the various methodological components.
EWAS analysis pipeline
1. Quality control
Illumina Infinium 450 K data are retrieved using the
minfi R package (version 1.2.0) [15] and downstream
analyses are performed using minfi and R. We
remove 65 single nucleotide polymorphism (SNP)
markers and apply Illumina Background Correction
to all intensity values. Methylation markers on
autosomes and gender chromosomes are analysed
separately. A detection P value threshold of P <10−16
was chosen and intensity values with detection
P ≥10−16 are set to missing data. We determine the
proportion of missing data points per sample,
enabling calculation of the sample call rate and
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remove samples with swapped gender labels
identified by high call rates for Y-chromosome
markers.
2. Quantile normalisation of intensity values
Intensity values are separated into six different
probe-type categories defined by colour channel,
probe-type and M/U subtype (Type-I M red, Type-I
U red, Type-I M green, Type-I U green, Type-II red,
Type-II green). Within each category intensity values
are quantile normalised using limma [32]. Normalised
intensity values are then used to calculate the
percentage methylation at each CpG site (beta value).
3. Control Probe Adjustment
We use intensity values from the Infinium 450 K
control probes (Additional file 1: Table S4) to adjust
for technical bias. Control probe intensities
(excluding negative control probes) are obtained
using minfi [15]. A PCA of the control probe
intensities is performed and the resulting PCs 1 to
30 are subsequently included as linear predictors in
regression models (steps 5 and 6).
4. Estimation of white blood cell sub-populations
Six white blood cell sub-populations are estimated
using the approach described by Houseman et al.
[26]. Estimates are based on 500 markers most
informative of white blood cell subpopulations as
measured by the Illumina Infinium 27 K methylation
array. Of these 470 are also present on the Illumina
Infinium 450 K methylation array and are therefore
used in this analysis. Estimated white blood cell
subpopulations (WBCest) and (measured) total
white blood cell counts (WBCtot) are subsequently
included as linear predictors in regression models
(steps 5 and 6).
5. PCA of intermediary residuals
To make a final correction for global covariation
that is still unaccounted for, we perform a linear
regression predicting the (quantile normalised) beta
values adjusted for technical and biological factors
and study-specific confounders such as gender and
age (1).
Beta QNð Þ
e
age þ gender þ WBCest
þWBCtot þ PC1−30ctrl−probes ð1ÞWe then perform a PCA on the resulting regression
residuals (excluding markers with missing data) and in-
clude PC 1 to 5 as linear predictors in the final regres-
sion model (step 6).6. Logistic regression analysis to identify differential
methylation
To detect differential methylation we perform a final
(logistic) regression analysis for each methylation
marker predicting disease status Y as a function of
the beta value adjusted for technical and biological
factors and PCs (2).
Y
e
Beta QNð Þ þ age þ gender þ WBCest
þWBCtot þ PC1−30ctrl−probes þ PC1−5 ð2Þ
Data generation
Two DNA methylation datasets were generated in this
study: (1) a population study of 2,687 samples (1,080
Type 2 Diabetes cases, 1,607 controls); and (2) a replica-
tion dataset of 36 samples measured in duplicate. Gen-
omic DNA was extracted from peripheral blood and
analysed in batches of 288 samples. To maximise the
impact of technical factors in the replication dataset, the
initial and repeat sample measurements were carried out
in separate batches. Methylation was quantified following
standard protocol (Infinium_HD_Methylation_Assay_
Guide_15019519_B) with 1 ug of DNA as starting material
and an elution volume of 14 uL after bisulphite conversion
(using the EZ-96 methylation kit; Zymo). Microarrays
were imaged using an Illumina HiScan scanner.
Initial quality control
Illumina Infinium 450 K data were retrieved as described
and an initial top-level Quality Control was performed
following the analysis recommendations given by the
array manufacturer. In brief, we applied Illumina Back-
ground Correction to all intensity values and calculate
the percentage methylation at each CpG site assayed
(the beta value). An initial detection P value threshold of
P <0.05 was chosen based on Illumina recommenda-
tions; beta values with detection P ≥0.05 were set to
missing data. We determined the proportion of missing
data points per sample and per marker, enabling calcula-
tion of sample and marker call rates, respectively. For
the population study we excluded 17 samples with
sample call rate <98%. We also removed five samples
with swapped gender labels identified by high call rates
for Y-chromosome markers. After re-evaluation of the
detection P value threshold, beta values with detection
P ≥10−16 were set to missing data. We re-calculated
sample call rates and excluded one further individual
with sample call rate <98% from the study.
Outliers and outlier rate
For each methylation marker we define outliers based
on the interquartile range (IQR), such that beta values
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1–1.5 × IQR or above Quartile 3 + 1.5 × IQR. Outlier
rates are calculated as the number of outlying beta
values divided by the number of non-missing beta
values.
Data normalisation
We evaluated 10 methods to data normalisation: (1)
quantile normalisation of beta values separated by
probe-type and colour channel (Type II, Type I red,
Type I green) using limma [32]; (2) quantile normalisa-
tion of intensity values separated by colour channel (red
and green channel; termed QN-I2) using limma [32]; (3)
quantile normalisation of intensity values separated by
colour channel and probe-type (Type I red, Type I green,
Type II red, Type II green; termed QN-I4) using limma
[32]; (4) quantile normalisation of intensity values sepa-
rated by colour channel, probe type and M/U subtypes
(Type I M red, Type I U red, Type I M green, Type I U
green, Type II red, Type II green; termed QN-I6) using
limma [32]; (5) Illumina Control Probe normalization as
implemented by minfi [15] (‘normalize.illumina.control’;
not to be confused with CPA); (6) subset within-array
normalisation (SWAN) [20]; (7) peak-based correction
[11]; (8) Beta MIxture Quantile dilation (BMIQ) [19]; (9)
subset quantile normalisation [14]; and (10) functional
normalisation (FN) [22]. All normalisation methods were
implemented using the R packages supplied with the
publications.
After each normalisation we determined the Pearson
correlation coefficients between replicates for the 36
samples measured in duplicate. Pearson correlation coef-
ficients are calculated (1) at the marker level: correlation
coefficient between the 36 paired measurements for each
of the 470,000 markers assayed (thus generating ap-
proximately 470,000 test results; Additional file 1: Figure
S6A); and (2) at the sample level: correlation co-efficient
between the paired measurements of the approximately
470,000 markers assayed in each of the 36 duplicate
samples (thus generating 36 test results; Additional file 1:
Figure S6B). A paired Wilcoxon test was used to assess
the difference between the normalisation methods.
To assess the degree of true signal detectable after
each normalisation method, we performed spike-in sim-
ulations. Based on the population study, disease labels
were randomised to generate 10 permutated datasets.
From each permuted dataset 100 markers were ran-
domly selected and spiked. For each ‘spike-marker’ raw
beta values of samples with a case label are increased by
a defined proportion of the standard deviation of the re-
spective marker. Based on these spiked beta values we
calculate intensity values for the methylated and the
unmethylated probe, such that for half of the spiked
probes the methylated intensity is changed and for theother half the unmethylated intensity is changed. Nega-
tive intensity values resulting from this process are set to
zero. Intensity values were spiked over a range of magni-
tudes (as percentage of SD of the beta value) resulting in
10 sets per magnitude (10 permutations per magnitude).
Using univariate logistic regression we calculated P values
for each permuted datasets and ranked the 100 spiked
markers by their association P values. For each magnitude
the 10 permuted dataset provide a total of 1,000 ranks for
1,000 spiked markers.
Analysis of technical replicates
To assess the degree of technical biases and batch ef-
fects, we analysed a technical replication dataset com-
prising 36 samples measured in duplicate. To maximise
the impact of technical factors the initial and repeat
sample analyses were carried out in separate batches.
We performed regression analyses to identify differen-
tially methylated positions between replicates. Using
paired linear regression we predict replicate status as a
function of the beta value with and without adjustments
for control probe PCs.
Replicate
e
Beta QNð Þ ð3Þ
Replicate
e
Beta QNð Þ þ PC1−30ctrl − probes ð4Þ
Batch correction using ComBat
We performed batch correction for technical technical
replication dataset based on quantile normalised beta
values using ComBat [25] to compare its performance to
CPA. ComBat, as implemented in ChAMP (champ.
runCombat) [16], performs a batch correction based
on the Bead-Chip (Sentrix ID) and returns corrected
methylation values. All samples measured on relevant
Bead-Chips were included for batch correction. To
avoid ComBat deliberately preserving differences at-
tributable to the outcome of interest (replicate status),
gender was defined as the Sample Group.
Permutations of the disease status
To make permutation-analysis of the large-scale popula-
tion study computationally tractable for 1,000 permuta-
tions we performed a linear regression of model (5) and
retrieved the residuals. These were used as predictors in
a logistic regression, with the (permuted) disease-status
(Yperm) as outcome (6). This approach is in almost per-
fect agreement with a conventional model that directly
adjusts for all linear predictors (2): we calculated coeffi-
cients of determination (R2-values) for -log(P values)
and beta-coefficients with respect to results from model
(2) and found R2 > 0.999 (analysis performed for permu-
tation 1 to 10).
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age þ gender þ WBCest þ WBCtot
þ PC1 − 30ctrl−probes þ PC1 − 5 ð5Þ
Yperm
e
residuals ð6Þ
Assessment of white blood cell estimates
For the population study estimated white blood cell sub-
populations (WBCest) explain a higher proportion of vari-
ance in the methylation data than measured white blood
cell subpopulations, which may reflect the wider range of
lymphocyte sub-classes in estimated sub-populations. Ad-
justment for white blood cells is therefore based on esti-
mated white blood cell sub-populations and (measured)
total white blood cell counts (WBCtot).
Analysis of global correlation patterns (heatmap)
To identify global correlation patterns that can be ex-
plained by biological factors, we performed a PCA based
on methylation residuals after quantile normalisation
(QN) and CPA (7). PCs were linked to multiple pheno-
types (age, gender, white blood cells, and so on) using
linear regression. P values of association (between the
PCs and the phenotypes) were Bonferroni-corrected and
plotted on the -log10 scale (Figure 4).
Beta QNð Þ
e
PC1 − 30ctrl − probes ð7Þ
Local correlation
Local correlation was determined for all possible pairs of
autosomal markers up to 5,000 bp apart. Distance be-
tween markers was based on the annotated position of
the CpG sites on the forward strand. Pearson correlation
coefficient between marker pairs were calculated based
on beta values (raw) and residuals derived from models
(5) and (7). A large proportion of methylation markers
show very little variation, which limits their ability to
yield high correlation coefficients. To reflect the effect of
genomic distance on correlation more appropriately we
therefore selected the 5% most variable markers (based
on raw beta values) and represent their correlation
graphically on a continuous scale using a sliding 300 bp
mean. To demonstrate that adjustments preferentially
reduced correlation between markers with greater dis-
tance we calculated the difference in correlation coeffi-
cients per basepair distance (between two different
adjustments). To determine statistical significance we
then performed a linear regression of the differences
and the genomic distance.
Performance
Spike-in simulations were carried out as described. Each
permuted dataset was then analysed using differentstages of the CPACOR pipeline and other published
450 k analysis pipelines [11-17] (where computationally
tractable). Only approaches providing a complete ana-
lysis pipeline from signal intensities to detection of dif-
ferentially methylated CpG sites were considered. For
each pipeline default parameters were chosen as speci-
fied and ranks were calculated as described.
Reference-free approaches
Using ‘spike-in’ data generated as described, we assessed
the performance of EWASher [30] and RefFreeEWAS
[31]. Beta values were quantile normalised and control-
probe PCs 1 to 30 were provided as covariates to adjust
for technical biases. Because neither approach was com-
putationally tractable for the complete dataset (2,664
samples), analysis was performed on a smaller dataset
(250 cases, 250 controls).
EWASher was applied to all CpGs (including constitu-
tively methylated CpGs). Default parameters were
chosen as specified and results of each analysis step (lin-
ear regression, linear mixed model regression, linear
mixed model regression + PCs) were retrieved.
Adjusted and unadjusted beta coefficients were calcu-
lated using RefFreeEWAS. Dimensionality was estimated
as described by Houseman et al. (d = 133) and default
parameters were chosen as specified. To derive P values
we performed 50 bootstraps, which required 50 hours of
compute time and 130 GB RAM.
Marker categories
We assessed the following probe types for their impact
on association test results:
1. Non-CpG markers. Autosomal probes that measure
methylation at CpA and CpT rather than CpG sites
(N = 2,995) based on the Illumina annotation.
2. Cross-mapping probes. Methylation probe
sequences reported to map to >1 genomic location
(N = 39,963) identified by Price et al. [18].
3. Probes with SNPs. Methylation markers with one or
more SNPs located within the probe sequence
(including the G-base of the CpG site) that have
minor allele frequency >1% in the samples studied.
(N = 75,702).
Sex chromosomes
Analysis of methylation markers on the sex chromosomes
was performed as described for autosomal markers, but
separately in males (chromosome X and Y) and females
(chromosome X). In addition to samples with autosomal
call rates <98% we excluded samples with chromosome X
and Y call rates <98%. This results in 1,780 samples for
chromosome Y (25 samples excluded), 1,802 for chromo-
some X in males (3 samples excluded) and 859 samples
Lehne et al. Genome Biology  (2015) 16:37 Page 11 of 12for chromosome X in females. Separately for each dataset
we performed quantile normalisation and adjusted for
control probe PCs, age, white blood cells and PC 1 to 5.
Data availability
Methylation array data can be accessed through the Gene
Expression Omnibus at http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE55763.
Additional files
Additional file 1: Contains all supplementary figures and tables.
Additional file 2: Contains scripts and documentation for the
CPACOR EWAS analysis pipeline. Files can be read using a standard
text-editor. Usage requires knowledge of R-programming and may have
to be adapted to accommodate the software and hardware requirements
specific to the user’s system.
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